CVS - CVS Health Corporation (CVS) Bernstein's 40th Annual Strategic Decisions Conference
2024-05-29 18:55:25 ET
CVS Health Corporation (CVS)
Bernstein's 40th Annual Strategic Decisions Conference
May 29, 2024 10:00 AM ET
Company Participants
Karen Lynch - President and CEO
Tom Cowhey - Executive Vice President and Chief Financial Officer
Conference Call Participants
Lance Wilkes - Bernstein
Presentation
Lance Wilkes
Okay. So we're going to kick-off. Let Tom, who is not the Interim CFO, but the CFO, speak to a few statements and then Karen is going to start-off with some introductory comments.
Tom Cowhey
Thanks, Lance. Thanks everyone for joining us. I just want to say that we will make forward-looking statements today. So we encourage everyone to please look at our risk factors that are in our SEC filings. You can access them through the SEC website or through the Investor portion of cvshealth.com
Karen Lynch
Thank you, Lance, for having us this morning. Really appreciate the opportunity. I just want to start with some opening comments. As you know with our recent performance has been disappointing to us, but it is reflective of one of our businesses. And I thought it was important this morning to talk about a fair amount of things that we have going on in our business, that you appreciate the broad portfolio of assets that we have.
As you know, our strategy is really to build a convenient, connected, personalized of integrated solutions company that is focused on the long lifetime value of a consumer. And as we know, consumers and patients who interact with the healthcare system, will deliver lower-cost, will have improved quality and eventually continue to drive growth for our company, because of the better outcomes and because of the better retention that we have with them.
But I thought it was important this morning to really highlight some of the things that are going on with the company that are going well before I talk about Medicare Advantage. In December, we talked about our strategic intent of doing a number of things relative to our business. We started and we talked about Cordavis, which is, in a way, a new approach to the biosimilar market. And in a very short period of time, one month, we have dispensed more biosimilars than the entire market did last year. And I think that speaks to -- speaks volumes to our ability to execute and our ability to drive down costs. As a result, we expect to see continued growth from that market....
CVS Health Corporation (CVS) Bernstein's 40th Annual Strategic Decisions Conference